Latest 8-K filings

Bed Bath & Beyond, Inc. announces the appointment of Jill Windrum as Chief Accounting Officer and Deputy Chief Financial Officer, effective August 31, 2026.

Cingulate Inc. announced its second quarter 2026 financial results, highlighting $28.4 million in cash, progress on CTx-1301 manufacturing, and a new patent, while navigating a delayed NDA resubmission.

PDS Biotechnology Corporation announced a strategic refocus on its PDS0301 program, discontinuing the VERSATILE-003 Phase 3 trial for PDS0101 and reporting a net loss of $9.8 million for Q2 2026.

Ovid Therapeutics reported Q2 2026 business updates and financial results, highlighting progress in its OV4071 and OV329 programs, a strategic soticlestat transaction, and strengthened leadership.

Fate Therapeutics announced second quarter 2026 financial results, highlighting progress in its CAR T-cell therapy pipeline, including patient dosing in a Phase 2 trial for lupus nephritis and FDA clearance for a new autoimmune trial.

HeartCore Enterprises announced second quarter 2026 financial results, showing a 71.6% revenue increase to $321,000 but a net loss of $2.0 million, a significant shift from the prior year's net income.

Tron Inc. announced a strategic initiative to deepen its integration with the TRON DAO ecosystem and pursue Super Representative status, aiming to generate recurring on-chain revenue.

FitLife Brands reported a 65% revenue increase in Q2 2026, largely due to the Irwin Naturals acquisition, alongside sequential growth and improved EPS.

SS Innovations International announced record second quarter 2026 revenue of $13.9 million, a 39.4% increase year-over-year, driven by strong sales of its SSi Mantra surgical robotic system.

Banzai International, Inc. has issued a new Senior Secured Convertible Note with an original principal amount of $1,099,989.00, convertible into shares of common stock.

Ondas Inc. announced record Q2 2026 revenue of $83.8 million, a 67% sequential increase and 13-fold year-over-year growth, while raising its full-year revenue target to $525-$550 million.

Sonida Senior Living, Inc. has entered into a new $380.0 million senior secured term loan with Ally Bank, amending and restating its existing agreement.

Lucid Diagnostics announced second quarter 2026 financial results, reporting $1.5 million in revenue and processing 2,770 EsoGuard tests, while also securing a key laboratory benefit manager coverage policy.

SPAR Group, Inc. announced its second quarter fiscal 2026 financial results, reporting a return to profitability with positive net income and increased Adjusted EBITDA, despite a year-over-year revenue decrease.

NeuroOne Medical Technologies Corporation announced a 16% year-over-year increase in product revenue to $2.0 million for its third fiscal quarter ended June 30, 2026, alongside a significant expansion in gross margins to 59.9%.

Candel Therapeutics announced Q2 2026 results, highlighting progress in its aglatimagene prostate cancer program with a planned BLA submission in Q4 2026 and positive Phase 3 data published in The Lancet Oncology.

Pulmatrix announces Q2 2026 results, highlighting progress on its merger with Eos Senolytix and efforts to out-license or monetize its clinical assets.

Solo Brands announced its fiscal 2026 second quarter results, highlighting improved profitability and significant debt reduction despite a dip in net sales.

MeiraGTx reports strong Q2 2026 results, highlighted by the acquisition of botaretigene sparoparvovec, a $400 million strategic investment, and positive clinical data for AAV2-hAQP1.

Duke Robotics Corp. announced its second quarter 2026 financial results, highlighting an expanded Israel Electric Corporation contract, a new defense order, and a successful $9.2 million public offering and Nasdaq uplisting.

Veea Inc. has entered into an At Market Issuance Sales Agreement with Roth Capital Partners, LLC, allowing for the sale of up to $4.35 million in common stock.

The Elmet Group Co. announced robust second quarter 2026 financial results, featuring a 35.2% increase in revenue to $66.4 million and a significant expansion in gross profit margin.

Monro, Inc. announced its annual meeting results, including the election of directors and the declaration of a quarterly cash dividend of $0.28 per share.

Grace Therapeutics announced its second quarter 2026 financial results, reporting a net loss of $15.8 million and providing an update on the ongoing efforts to resubmit its New Drug Application for GTx-104.

Venu Holding Corporation announced its second-quarter 2026 financial results, showcasing a substantial increase in total assets and progress on venue development and financing strategies.

Healthy Choice Wellness Corp. announced a 15-year, $1.25 billion take-or-pay lease agreement for 43 MW of IT load capacity at its Oklahoma data center.

Artius II Acquisition Inc. announced its board has decided to liquidate and dissolve the company as it cannot complete its initial business combination within the required timeframe.

Rekor Systems announced Q2 2026 results, showcasing a 23% sequential revenue increase to $12.7 million, improved adjusted gross margin to 56%, and a 79% year-over-year reduction in adjusted EBITDA loss.

SCI Engineered Materials, Inc. has announced a management transition with the resignation of its Chief Financial Officer, Shelby Yohn, who will remain with the company in a new role.

Accelerant Holdings announced a definitive agreement to be acquired by Thoma Bravo in an all-cash transaction valued at over $4 billion, while also reporting strong Q2 2026 financial results.